Page last updated: 2024-10-26

dipyridamole and Brain Ischemia

dipyridamole has been researched along with Brain Ischemia in 128 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs."9.16Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012)
"Treatment with combined Asp/ER-DP vs clopidogrel in 1360 patients with acute, mild ischemic stroke did not differ in terms of effects on functional outcome, recurrence, death, bleeding, or serious adverse events."9.14Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."9.13Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
"This pilot study showed equal efficacy and tolerability of the combination group and aspirin alone in acute intervention treatment for prevention of recurrent stroke or vascular death within 6 months."9.11Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005)
" Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials."9.11Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005)
"The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone."9.11Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004)
"It is unlikely that dipyridamole leads to a permanent reduction in blood pressure and that this would explain why this drug might prevent strokes rather than coronary events."9.10Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003)
"Randomized controlled trials involving dipyridamole in patients with previous ischemic stroke or TIA were sought from searches of the Cochrane Library, other electronic databases, references lists, earlier reviews, and contact with the manufacturer of dipyridamole."8.82Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005)
"This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin."8.12Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022)
"Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)."7.80Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014)
"Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone."7.78Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012)
"A considerable proportion of patients discontinue dipyridamole therapy because of headache."7.75Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009)
"Given that isotretinoin is a treatment prescribed most frequently for adolescents and young adults and that cerebral ischemia can produce serious handicaps, an evaluation of vascular risk should be made prior to treatment with this drug."7.74Cerebral ischemia probably related to isotretinoin. ( Laroche, ML; Macian-Montoro, F; Merle, L; Vallat, JM, 2007)
"Despite improvements in treatment, stroke still carries a high death toll and disability in Asia."6.76The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011)
"Dipyridamole was introduced into clinical medicine in the early 1960s as a coronary vasodilator."6.46Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia. ( Cipriani, S; Corti, F; Melani, A; Pedata, F, 2010)
"A review is given on the clinical studies performed with aspirin in patients with chronic vascular occlusions of the limbs and on studies in cerebral ischemia using aspirin and sulfinpyrazone."6.14Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders. ( Breddin, K, 1977)
"Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke."5.20Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. ( Bath, PM; Dineen, R; Pocock, S; Robson, K; Sprigg, N; Woodhouse, LJ, 2015)
"Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs."5.16Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012)
"Treatment with combined Asp/ER-DP vs clopidogrel in 1360 patients with acute, mild ischemic stroke did not differ in terms of effects on functional outcome, recurrence, death, bleeding, or serious adverse events."5.14Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."5.13Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
" The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomised to aspirin 30-325 mg daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily."5.12ESPRIT study design and outcomes--a critical appraisal. ( Einhäupl, K, 2007)
"This pilot study showed equal efficacy and tolerability of the combination group and aspirin alone in acute intervention treatment for prevention of recurrent stroke or vascular death within 6 months."5.11Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005)
" Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials."5.11Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005)
"The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone."5.11Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004)
"It is unlikely that dipyridamole leads to a permanent reduction in blood pressure and that this would explain why this drug might prevent strokes rather than coronary events."5.10Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003)
"We compared the outcomes of 2,500 patients who suffered from previous cerebrovascular disorders (transient ischemic attacks, reversible ischemic neurologic deficits, or completed strokes) treated with acetylsalicylic acid plus dipyridamole or matched placebo and followed for 2 years."5.06European Stroke Prevention Study. ESPS Group. ( , 1990)
"Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved."4.90Oral antiplatelet therapy for acute ischaemic stroke. ( Cecconi, E; Counsell, C; Sandercock, PA; Tseng, MC, 2014)
"Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0."4.89Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013)
" In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3."4.88Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012)
"A 23-year-old woman developed ischemic stroke (IS) 8 to 12 hours after ingestion of sumatriptan (ST) and then developed mucosal bleeding secondary to acute thrombocytopenia likely due to dipyridamole (DP) on the 10th day poststroke."4.87Ischemic stroke followed by acute thrombocytopenia: a double iatrogenic whammy. ( Adams, C; Ames, PR; Dhirendra, A, 2011)
"To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease."4.87Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011)
"In primary prevention trials conducted in low-risk subjects, aspirin is associated with a small reduction in ischemic strokes in women."4.85Antiplatelet drugs for ischemic stroke prevention. ( Balucani, C; Cordonnier, C; Leys, D, 2009)
" Currently, aspirin is generally prescribed for the primary prevention of stroke despite a number of trial results on effectiveness proving inconclusive."4.85Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease? ( Beckman, JA, 2009)
"In this paper, an overview is given of trials with oral anticoagulants and dipyridamole in the secondary prevention after transient ischaemic attack or minor stroke."4.84Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient? ( Algra, A; Halkes, PH, 2007)
"Randomized controlled trials involving dipyridamole in patients with previous ischemic stroke or TIA were sought from searches of the Cochrane Library, other electronic databases, references lists, earlier reviews, and contact with the manufacturer of dipyridamole."4.82Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005)
"This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin."4.12Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022)
"In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke."3.81Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015)
"Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)."3.80Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014)
"Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone."3.78Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012)
"Administrative claims from a large, geographically diverse US health plan were used to evaluate acetylsalicylic acid / extended-release dipyridamole (ASA/ERDP) treated and clopidogrel treated patients from November 1, 2002 - December 31, 2005 who had an ischemic stroke requiring hospitalization."3.76Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. ( Burke, JP; Henk, H; Sander, S; Shah, H; Zarotsky, V, 2010)
"A considerable proportion of patients discontinue dipyridamole therapy because of headache."3.75Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009)
"Given that isotretinoin is a treatment prescribed most frequently for adolescents and young adults and that cerebral ischemia can produce serious handicaps, an evaluation of vascular risk should be made prior to treatment with this drug."3.74Cerebral ischemia probably related to isotretinoin. ( Laroche, ML; Macian-Montoro, F; Merle, L; Vallat, JM, 2007)
"In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)."3.74[Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007)
"Using a rat model of cerebral ischemia, the ENT1 inhibitor nitrobenzylmercaptopurine ribonucleoside (NBMPR) significantly increased post-ischemic forebrain adenosine levels and significantly decreased hippocampal neuron injury relative to saline-treatment."3.73Astrocytes and neurons: different roles in regulating adenosine levels. ( Parkinson, FE; Xiong, W; Zamzow, CR, 2005)
"Individual patient data of the second European Stroke Prevention Study (n=6602), in which patients with a previous transient ischemic attack or ischemic stroke were randomized to aspirin, dipyridamole, their combination, or placebo, were reanalyzed."3.73Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. ( Algra, A; Ariesen, MJ; Kappelle, LJ, 2006)
"In the recently published Warfarin Aspirin Recurrent Stroke Study (WARSS), a low-intensity anticoagulation regimen was used because of safety concerns."3.72Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. ( , 2003)
" Therefore, it was aimed to study whether dipyridamole (CAS 58-32-2), an adenosine uptake inhibitor, or adenosine (CAS 58-61-7) could affect the rat brain gamma-aminobutyric acid (GABA, CAS 56-12-2) level after induction of cerebral ischemia, and to test their effect on the lactate dehydrogenase (LDH) activity of the ischemic rat brain."3.71Influence of inhibition of adenosine uptake on the gamma-aminobutyric acid level of the ischemic rat brain. ( Khattab, M; Seif-el-Nasr, M, 2002)
" Apart from the standard remedies, the authors administered drugs affecting the syndrome of disseminated intravascular coagulation, such as dipyridamole, glutamic acid and phytin, with heparin and freshly frozen plasma containing antithrombin III employed in grave cases."3.67[Treatment of the syndrome of disseminated intravascular coagulation in ischemic strokes]. ( Bova, IIa; Karlov, VA; Makarov, VA, 1984)
"Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none."3.30Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. ( Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ, 2023)
"Despite improvements in treatment, stroke still carries a high death toll and disability in Asia."2.76The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011)
"Only aspirin has been evaluated in the setting of primary prevention and it seems to be ineffective in preventing cerebral infarction."2.68[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors]. ( Canaple, S; Rosa, A, 1996)
"The number of fatal and non fatal cerebral infarction was 31 in the P group, 17 in the ASA group, and 18 in the ASA + D group."2.65[The A.I.C.L.A. controlled cooperative trial. Secondary prevention of cerebral ischemic accidents due to atherosclerosis by aspirin and dipyridamole. 3: Results]. ( Bousser, MG; Eschwege, E; Haguenau, M; Lefauconnier, JM; Thibult, N; Touboul, D; Touboul, PJ, 1983)
"Predictive performance in patients with cerebral ischemia was poor."2.53Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. ( Algra, A; Greving, JP; Hilkens, NA, 2016)
"Dipyridamole was introduced into clinical medicine in the early 1960s as a coronary vasodilator."2.46Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia. ( Cipriani, S; Corti, F; Melani, A; Pedata, F, 2010)
"Stroke is a leading cause of death and the primary cause of serious, long-term disability in the United States."2.44Combination antiplatelet agents for secondary prevention of ischemic stroke. ( Saseen, JJ; Vande Griend, JP, 2008)
"About 80% of strokes have ischemic origin."2.43[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005)
"Ticlopidine is a reserve drug due to its unfavorable side effect profile (neutropenia, TTP)."2.42[The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review]. ( Jüttler, E; Meyding-Lamadé, UK; Schellinger, PD; Schwark, C, 2004)
"Aspirin treatment does not preclude control of underlying and comorbid conditions such as diabetes mellitus, hypertension, and dyslipidemia."2.41Aspirin in the prophylaxis of coronary artery disease. ( Mehta, P, 2002)
"The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes."1.37Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011)
"We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)."1.36Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. ( Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010)
" In these patients, we recommend use of the combination of aspirin and extended-release dipyridamole (25/200 mg bid) over aspirin (Grade 1A) and suggest clopidogrel over aspirin (Grade 2B), and recommend avoiding long-term use of the combination of aspirin and clopidogrel (Grade 1B)."1.35Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Albers, GW; Amarenco, P; Easton, JD; Sacco, RL; Teal, P, 2008)
"Stroke is associated with elevation of several proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-8 that are correlated with central nervous system (CNS) injury."1.34TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. ( Al-Bahrani, A; Bakhiet, M; Shaath, H; Taha, S, 2007)
"Dipyridamole (0."1.29Brain SPECT with dipyridamole stress to evaluate cerebral blood flow reserve in carotid artery disease. ( Brannon, WL; Farrell, JJ; Hwang, TL; Saenz, A, 1996)
"62 patients with transient ischemic attack (TIA), 60 with reversible ischemic neurologic deficit (RIND) and 57 with stroke with minimum residuum (SMR) were followed, in a retrospective survey, from the first 7 days to the 3rd month of evolution."1.27Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum. ( Calandre, L; Molina, JA, 1985)
"Mitral valve prolapse is usually a benign condition, however, serious complications have been reported to be associated with it."1.27Mitral valve prolapse and thromboembolic disease in pregnancy: a case report. ( Bergh, PA; Breen, JL; Gregori, CA; Hollander, D, 1988)
"When dipyridamole was infused in 11 healthy subjects, the adenosine level was not significantly elevated but the platelet aggregation was inhibited (from 13 to 11 ohms, p less than 0."1.27Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole. ( Edlund, A; Sidén, A; Sollevi, A, 1987)

Research

Studies (128)

TimeframeStudies, this research(%)All Research%
pre-199026 (20.31)18.7374
1990's18 (14.06)18.2507
2000's49 (38.28)29.6817
2010's31 (24.22)24.3611
2020's4 (3.13)2.80

Authors

AuthorsStudies
Shah, J1
Liu, S1
Yu, W1
Lim, ST1
Murphy, SJX1
Murphy, SM1
Coughlan, T2
O'Neill, D2
Tierney, S1
Egan, B1
Collins, DR1
McCarthy, AJ1
Lim, SY1
Smith, DR1
Cox, D2
McCabe, DJH1
Woodhouse, LJ4
Appleton, JP3
Christensen, H3
Dineen, RA3
England, TJ3
James, M3
Krishnan, K3
Montgomery, AA2
Ranta, A3
Robinson, TG3
Sprigg, N4
Bath, PM10
Kimpton, J1
Khong, T1
Lana, D1
Ugolini, F1
Melani, A2
Nosi, D1
Pedata, F2
Giovannini, MG1
Beridze, M2
Duley, L2
Flaherty, K2
Havard, D1
Heptinstall, S3
Markus, HS3
Pocock, SJ1
Randall, M1
Scutt, P2
Venables, GS2
Barlas, RS1
Loke, YK1
Mamas, MA1
Bettencourt-Silva, JH1
Ford, I1
Clark, AB1
Bowles, KM1
Metcalf, AK1
Potter, JF1
Myint, PK1
Lee, M1
Saver, JL2
Hong, KS1
Rao, NM1
Wu, YL1
Ovbiagele, B2
Sandercock, PA1
Counsell, C1
Tseng, MC1
Cecconi, E1
Davidai, G1
Cotton, D4
Gorelick, P3
Lipton, RB1
Sacco, R2
Diener, HC9
Robson, K1
Dineen, R1
Pocock, S2
Fabiaña, N1
Ramaswami, AP1
Ang, ES1
De Silva, DA1
Christiansen, CB1
Pallisgaard, J1
Gerds, TA1
Olesen, JB1
Jørgensen, ME1
Numé, AK1
Carlson, N1
Kristensen, SL1
Gislason, G1
Torp-Pedersen, C1
Hilkens, NA1
Algra, A9
Greving, JP1
Murphy, SJ1
Coughlan, CA1
Tobin, O1
Kinsella, J1
Lonergan, R1
Gutkin, M1
McCabe, DJ2
Sztriha, LK1
Vécsei, L1
Albers, GW2
Amarenco, P1
Easton, JD1
Sacco, RL4
Teal, P2
Yusuf, S3
Ounpuu, S1
Lawton, WA1
Palesch, Y2
Martin, RH3
Bath, P2
Bornstein, N1
Chan, BP1
Chen, ST1
Cunha, L2
Dahlöf, B1
De Keyser, J1
Donnan, GA2
Estol, C2
Gu, V1
Hermansson, K2
Hilbrich, L1
Kaste, M2
Lu, C1
Machnig, T1
Pais, P1
Roberts, R2
Skvortsova, V1
Toni, D1
Vandermaelen, C1
Voigt, T1
Weber, M1
Yoon, BW1
Vande Griend, JP1
Saseen, JJ1
Minnerup, J1
Schäbitz, WR1
Hart, RG1
Hegge, KA1
Halkes, PH2
van Gijn, J2
Kappelle, LJ2
Koudstaal, PJ2
Leys, D1
Balucani, C1
Cordonnier, C1
Biller, J1
De Schryver, EL3
Beckman, JA1
Adams, C1
Dhirendra, A1
Ames, PR1
Gomez, CR1
Qureshi, AI1
Meyer, D1
Diedler, J1
Ahmed, N1
Sykora, M1
Uyttenboogaart, M1
Overgaard, K2
Luijckx, GJ1
Soinne, L1
Ford, GA1
Lees, KR2
Wahlgren, N1
Ringleb, P1
Burke, JP1
Sander, S1
Shah, H1
Zarotsky, V1
Henk, H1
Cipriani, S1
Corti, F1
Serebruany, V1
Sani, Y1
Pokov, I1
Schevchuck, A1
Fong, A1
Thevathasan, L1
Hanley, D1
Khan, M1
Kamal, AK2
Uchiyama, S1
Ikeda, Y1
Urano, Y1
Horie, Y1
Yamaguchi, T1
Greenhalgh, J1
Bagust, A1
Boland, A1
Martin Saborido, C1
Oyee, J1
Blundell, M1
Dundar, Y1
Dickson, R1
Proudlove, C1
Fisher, M1
Vinisko, R1
Weber, R1
Weimar, C1
Wanke, I1
Möller-Hartmann, C1
Gizewski, ER1
Blatchford, J1
Demchuk, AM1
Forsting, M1
Warach, S1
Diehl, A1
Acelajado, MC1
Oparil, S1
Geeganage, CM1
Chen, C1
Topol, EJ1
Dengler, R2
Bath, MW1
Arnarsdottir, L1
Hjalmarsson, C1
Bokemark, L1
Andersson, B1
Worthmann, H1
Schumacher, H1
Schwartz, A1
Eisert, WG1
Lichtinghagen, R1
Weissenborn, K1
Kinsella, JA1
Tobin, WO1
Collins, R1
Murphy, RP1
Wadiwala, MF1
Milionis, H1
Michel, P1
Mehta, P1
Aslanyan, S1
Fazekas, F1
Weir, CJ1
Horner, S1
Schellinger, PD3
Jüttler, E1
Meyding-Lamadé, UK1
Schwark, C2
Serebruany, VL1
Malinin, AI1
Sane, DC1
Jilma, B1
Takserman, A1
Atar, D1
Hennekens, CH1
Leonardi-Bee, J3
Bousser, MG5
Davalos, A2
Guiraud-Chaumeil, B1
Sivenius, J3
Yatsu, F1
Dewey, ME1
Moussouttas, M2
Papamitsakis, N1
Zhao, L2
Fletcher, S1
Weaver, C1
May, J1
Fox, S1
Willmot, M1
Heptinstal, S1
Ringleb, PA1
Schwaninger, M1
Parkinson, FE1
Xiong, W1
Zamzow, CR1
Szapáry, L1
Ariesen, MJ1
Gray, L1
Weaver, CS1
Jonas, S1
Grieco, G1
Chairangsarit, P1
Sithinamsuwan, P1
Niyasom, S1
Udommongkol, C1
Nidhinandana, S1
Suwantamee, J1
O'Donnell, M1
Eikelboom, JW1
Flaherty, ML1
Kissela, B1
Broderick, JP1
Derendorf, H1
Einhäupl, K1
Al-Bahrani, A1
Taha, S1
Shaath, H1
Bakhiet, M1
Sudlow, C1
Laroche, ML1
Macian-Montoro, F1
Merle, L1
Vallat, JM1
Poulsen, TS1
Husted, SE1
Rojas, A1
González, I1
Figueroa, H1
Hallevi, H1
Hazan-Hallevi, I1
Paran, E1
Adams, RJ1
Albers, G1
Alberts, MJ1
Benavente, O1
Furie, K1
Goldstein, LB1
Halperin, J1
Harbaugh, R1
Johnston, SC1
Katzan, I1
Kelly-Hayes, M1
Kenton, EJ1
Marks, M1
Schwamm, LH1
Nielsen, AA1
Veien, KT1
Jørgensen, LG1
Buck, TC1
Brandslund, I1
Christensen, C1
Skliut, M1
Jamieson, DG1
Karlov, VA1
Makarov, VA1
Bova, IIa1
Hinton, RC1
Eschwege, E3
Haguenau, M3
Lefauconnier, JM3
Thibult, N2
Touboul, D3
Touboul, PJ3
Ordinas, A1
Sancho Rieger, J1
López-Trigo Picho, J1
Burtsev, EM1
Usov, LA1
Atamaniuk, ED1
Miller, LG1
Hansen, PE1
Hansen, JH1
Stenbjerg, S1
Marshall, M1
Cauchie, C1
Croveri, G1
Santos, MT1
Vallés, J2
Aznar, J2
Yayá, R2
Perez-Requejo, JL1
Hegedüs, K1
Fekete, I1
Molnár, L1
Díaz-Marín, C1
Matías-Guiu, J2
Hwang, TL1
Saenz, A1
Farrell, JJ1
Brannon, WL1
Rosa, A1
Canaple, S1
Rosendaal, FR1
Orberk, E1
Hacke, W1
Gorter, JW1
Boysen, G1
Forbes, C1
Laakso, M1
Lowenthal, A1
Smets, P1
Riekkinen, P2
Scott, G1
Scott, HM1
Mosso, M1
Baumgartner, RW1
Stakhovskaia, LV1
Kvasova, OV1
Prianikova, NA1
Efremova, NM1
Skvortsova, VI1
Bergmann, SR1
Seif-el-Nasr, M1
Khattab, M1
Breddin, K1
Urbinati, S1
Di Pasquale, G1
Andreoli, A1
Lusa, AM1
Lanzino, G1
Grazi, P1
Ruffini, M1
Labanti, G1
Pinelli, G1
Fogelholm, R1
Park, TS1
Gidday, JM1
Calandre, L1
Molina, JA1
Chrobocek, J1
Phillis, JW1
O'Regan, MH1
Walter, GA1
Caneschi, S1
Bonaventi, C1
Finzi, F1
Bergh, PA1
Hollander, D1
Gregori, CA1
Breen, JL1
Joseph, R1
D'Andrea, G1
Oster, SB1
Welch, KM1
Gordon, RL1
Haskell, L1
Hirsch, M1
Shifrin, E1
Weinman, E1
Romanoff, H1
Picó, M1
Monasterio, J1
Vilaseca, J1
Codina, A1
Edlund, A1
Sidén, A1
Sollevi, A1
Yamashita, T1
Kikuchi, H1
Ihara, I1
Matsumoto, A1
Vinichuk, SM1
Malyĭ, VD1
Vayá, A1
Villa, P1
Santos, T1
Martinez-Sales, V1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029]Phase 34,881 participants (Actual)Interventional2010-05-28Terminated (stopped due to The trial was halted by the DSMB.)
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062]Phase 420,332 participants (Actual)Interventional2003-08-31Completed
A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969]Phase 42,200 participants (Actual)Interventional2016-04-30Completed
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid[NCT00311402]Phase 31,295 participants (Actual)Interventional2006-04-30Completed
"PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314]142 participants (Actual)Interventional2019-11-20Completed
Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction[NCT03318744]3,400 participants (Anticipated)Interventional2018-01-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage

Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel141
Placebo167

Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes

Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel121
Placebo160

Death From Any Cause

Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel18
Placebo12

Death From Ischemic Vascular Causes

Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel6
Placebo4

Hemorrhagic Stroke

Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel5
Placebo3

Ischemic or Hemorrhagic Stroke

Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel116
Placebo156

Ischemic Stroke

Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel112
Placebo155

Major Hemorrhage

Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel23
Placebo10

Major Hemorrhage Other Than Intracranial Hemorrhage

Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel17
Placebo7

Minor Hemorrhage

Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel40
Placebo13

Myocardial Infarction

Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel10
Placebo7

Other Symptomatic Intracranial Hemorrhage

Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo0

Symptomatic Intracerebral Hemorrhage

Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo2

Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)

Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole1333
Clopidogrel1333

Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)

Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan1367
Placebo1463

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole916
Clopidogrel898

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan880
Placebo934

Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: Randomization to final patient contact

InterventionParticipants (Number)
Telmisartan125
Placebo151

Number of Patients With Acute Coronary Syndrome (ACS)

ACS contains acute myocardial infarction (MI), unstable angina and sudden cardiac death. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule9
Acetylsalicylic Acid (ASA) 81 mg Tablet16

Number of Patients With Brain (Cerebral) Haemorrhage

All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule12
Acetylsalicylic Acid (ASA) 81 mg Tablet7

Number of Patients With Composite Endpoint of Stroke or Major Bleeding

This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage, subarachnoid haemorrhage and major bleeding. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule71
Acetylsalicylic Acid (ASA) 81 mg Tablet55

Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal)

All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule45
Acetylsalicylic Acid (ASA) 81 mg Tablet32

Number of Patients With Intracranial Haemorrhage

All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule13
Acetylsalicylic Acid (ASA) 81 mg Tablet13

Number of Patients With Ischemic Vascular Event Composite Endpoint

This is a composite endpoint of cerebral infarction, transient ischemic attack (TIA), acute myocardial infarction (MI), unstable angina and sudden death attributable to thromboembolism. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule57
Acetylsalicylic Acid (ASA) 81 mg Tablet51

Number of Patients With Other Vascular Events

This endpoints were defined as pulmonary embolism, retinal vascular disorder, deep vein thrombosis, peripheral artery obstruction and vascular intervention. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule11
Acetylsalicylic Acid (ASA) 81 mg Tablet6

Number of Patients With Stroke

This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage and subarachnoid haemorrhage. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule57
Acetylsalicylic Acid (ASA) 81 mg Tablet39

Number of Patients With Subarachnoid Haemorrhage

All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule0
Acetylsalicylic Acid (ASA) 81 mg Tablet1

Number of Patients With Transient Ischemic Attack (TIA)

All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule3
Acetylsalicylic Acid (ASA) 81 mg Tablet3

Reviews

35 reviews available for dipyridamole and Brain Ischemia

ArticleYear
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
    Stroke and vascular neurology, 2022, Volume: 7, Issue:5

    Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient;

2022
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
    Annals of internal medicine, 2013, Oct-01, Volume: 159, Issue:7

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human

2013
Oral antiplatelet therapy for acute ischaemic stroke.
    The Cochrane database of systematic reviews, 2014, Mar-26, Issue:3

    Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlle

2014
Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study.
    Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:1

    Topics: Algorithms; Anticoagulants; Aspirin; Brain Ischemia; Calibration; Cerebral Hemorrhage; Dipyridamole;

2016
Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Pharmacotherapy, 2008, Volume: 28, Issue:10

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combinat

2008
Multifunctional actions of approved and candidate stroke drugs.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009, Volume: 6, Issue:1

    Topics: Albumins; Animals; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Cytidine Diphospha

2009
What's new in stroke? The top 10 studies of 2006-2008. Part I.
    Polskie Archiwum Medycyny Wewnetrznej, 2008, Volume: 118, Issue:11

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici

2008
Antiplatelet agents for prevention of recurrent ischemic stroke.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2009, Volume: 62, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Practic

2009
Antiplatelet drugs for ischemic stroke prevention.
    Cerebrovascular diseases (Basel, Switzerland), 2009, Volume: 27 Suppl 1

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination;

2009
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Journal of the neurological sciences, 2009, Sep-15, Volume: 284, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic;

2009
Secondary stroke prevention with antithrombotic drugs.
    Current vascular pharmacology, 2010, Volume: 8, Issue:1

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Cyclooxygenase Inhibitors; Dipyridamole; Drug

2010
Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jul-01, Volume: 74 Suppl 1

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy,

2009
Ischemic stroke followed by acute thrombocytopenia: a double iatrogenic whammy.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2011, Volume: 17, Issue:1

    Topics: Acute Disease; Adult; Brain Ischemia; Dipyridamole; Female; Hemorrhage; Humans; Iatrogenic Disease;

2011
Antiplatelets and stroke outcomes: state of the science.
    Critical care nursing clinics of North America, 2009, Volume: 21, Issue:4

    Topics: Arachidonic Acid; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Clopidogrel; Dipy

2009
Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia.
    Annals of the New York Academy of Sciences, 2010, Volume: 1207

    Topics: Animals; Brain Ischemia; Carotid Artery, Common; Dipyridamole; Disease Models, Animal; Humans; Infus

2010
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:31

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac

2011
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
    Stroke, 2012, Volume: 43, Issue:4

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab

2012
Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prevention strategy?
    Current pharmaceutical design, 2013, Volume: 19, Issue:21

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Life S

2013
Aspirin in the prophylaxis of coronary artery disease.
    Current opinion in cardiology, 2002, Volume: 17, Issue:5

    Topics: Aspirin; Brain Ischemia; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Humans; Myocardi

2002
[The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review].
    Fortschritte der Neurologie-Psychiatrie, 2004, Volume: 72, Issue:5

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Dose-Response Relation

2004
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
    Stroke, 2005, Volume: 36, Issue:1

    Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Humans; Is

2005
Combination antiplatelet agents in ischemic cerebrovascular disease.
    The Mount Sinai journal of medicine, New York, 2005, Volume: 72, Issue:1

    Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Combinati

2005
Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:3

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Health Care Costs; Humans

2005
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
    Orvosi hetilap, 2005, Oct-09, Volume: 146, Issue:41

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel;

2005
Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIA.
    BMJ (Clinical research ed.), 2007, Apr-28, Volume: 334, Issue:7599

    Topics: Aspirin; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient

2007
The PRoFESS trial: future impact on secondary stroke prevention.
    Expert review of neurotherapeutics, 2007, Volume: 7, Issue:9

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid

2007
Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient?
    Cerebrovascular diseases (Basel, Switzerland), 2007, Volume: 24 Suppl 1

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stro

2007
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
    Current cardiology reports, 2008, Volume: 10, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dipyridamole; Female; Humans; Ischemi

2008
[Place of antiplatelet agents in the prevention of cerebral ischemic strokes].
    Annales de medecine interne, 1983, Volume: 134, Issue:2

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Clofib

1983
[Current clinical results of antiplatelet medication].
    Sangre, 1984, Volume: 29, Issue:4-C

    Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; Dipyridamole; D

1984
[Antithrombotic therapy after cerebral ischemia].
    Fortschritte der Neurologie-Psychiatrie, 1997, Volume: 65, Issue:9

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy,

1997
[Secondary prevention following cerebral ischemia: is monotherapy with acetylsalicylic acid still first choice?].
    Nederlands tijdschrift voor geneeskunde, 1998, Feb-07, Volume: 142, Issue:6

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel

1998
[Transient ischemic attacks and prolonged reversible ischemic neurologic deficit. Diagnosis, differential diagnosis and treatment].
    Praxis, 2000, Mar-23, Volume: 89, Issue:13

    Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Diagnosis, Differential; Dipyridamole; Endarterectomy,

2000
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
    Bibliotheca haematologica, 1977, Volume: 44

    Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial

1977
[The use of drugs that affect thrombocytes in cerebral ischemia].
    Duodecim; laaketieteellinen aikakauskirja, 1990, Volume: 106, Issue:11

    Topics: Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Female; Humans; Male; Ticlopidine

1990

Trials

30 trials available for dipyridamole and Brain Ischemia

ArticleYear
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
    Scientific reports, 2023, 07-20, Volume: 13, Issue:1

    Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female

2023
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
    Lancet (London, England), 2018, 03-03, Volume: 391, Issue:10123

    Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb

2018
Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:3

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Double-Blind Method; Female; Humans; Internation

2015
Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
    International journal of stroke : official journal of the International Stroke Society, 2017, Volume: 12, Issue:5

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans;

2017
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
    Stroke, 2010, Volume: 41, Issue:4

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Female; Fibrinolytic Agents; Humans; Kapla

2010
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
    Cerebrovascular diseases (Basel, Switzerland), 2011, Volume: 31, Issue:6

    Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action

2011
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
    Cerebrovascular diseases (Basel, Switzerland), 2011, Volume: 31, Issue:6

    Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action

2011
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
    Cerebrovascular diseases (Basel, Switzerland), 2011, Volume: 31, Issue:6

    Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action

2011
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
    Cerebrovascular diseases (Basel, Switzerland), 2011, Volume: 31, Issue:6

    Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action

2011
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke.
    BMC neurology, 2012, Aug-06, Volume: 12

    Topics: Aged; Aspirin; Brain Ischemia; Comorbidity; Dipyridamole; Drug Therapy, Combination; Female; Humans;

2012
Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke.
    International journal of molecular sciences, 2012, Volume: 13, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Chemokine CCL2; Dipyridamole; D

2012
What is better antiplatelet agent to prevent recurrent stroke?
    JPMA. The Journal of the Pakistan Medical Association, 2012, Volume: 62, Issue:9

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid

2012
Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure.
    Stroke, 2003, Volume: 34, Issue:10

    Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up

2003
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
    European journal of pharmacology, 2004, Sep-24, Volume: 499, Issue:3

    Topics: Aged; Antigens, CD; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; CD40 Ligand; Di

2004
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke.
    Thrombosis and haemostasis, 2005, Volume: 93, Issue:3

    Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Cell Adhesion; Clopidog

2005
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke.
    Platelets, 2006, Volume: 17, Issue:2

    Topics: Adult; Arteriosclerosis; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; C-Reactive Protein; C

2006
Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88 Suppl 3

    Topics: Aged; Aspirin; Brain Ischemia; Dipyridamole; Drug Administration Schedule; Drug Therapy, Combination

2005
ESPRIT study design and outcomes--a critical appraisal.
    Current medical research and opinion, 2007, Volume: 23, Issue:2

    Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H

2007
[Place of antiplatelet agents in the prevention of cerebral ischemic strokes].
    Annales de medecine interne, 1983, Volume: 134, Issue:2

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Clofib

1983
[The A.I.C.L.A. controlled cooperative trial. Secondary prevention of cerebral ischemic accidents due to atherosclerosis by aspirin and dipyridamole. 3: Results].
    Revue neurologique, 1983, Volume: 139, Issue:5

    Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Clinical Trials as Topic; Dipyridamole; Drug Therapy,

1983
["A.I.C.L.A." controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Part I: Protocol (author's transl)].
    Revue neurologique, 1981, Volume: 137, Issue:5

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans;

1981
[Controlled cooperative trial. Secondary prevention of atherosclerosis-related cerebral ischemic accidents by aspirin dipyridamole. 2: Description of subjects at the beginning of the trial].
    Revue neurologique, 1982, Volume: 138, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Cerebral Infarction; Clinical Trials as Topic; Dipyridamole; Drug The

1982
[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
    Archives des maladies du coeur et des vaisseaux, 1996, Volume: 89, Issue:11 Suppl

    Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Dose-Response Re

1996
[Prevention of vascular complications following cerebral ischemia of arterial origin; the ESPRIT trial: mild anticoagulant therapy, combination treatment with acetylsalicylic acid plus dipyridamole or treatment with acetylsalicylic acid alone?].
    Nederlands tijdschrift voor geneeskunde, 1998, Feb-07, Volume: 142, Issue:6

    Topics: Adult; Aged; Anticoagulants; Antifibrinolytic Agents; Aspirin; Brain Ischemia; Cerebrovascular Disor

1998
Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group.
    Acta neurologica Scandinavica, 1999, Volume: 99, Issue:1

    Topics: Administration, Oral; Adult; Age Factors; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders;

1999
[The administration of dipyridamole (curantil) for the secondary prevention of ischemic stroke].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2000, Volume: 100, Issue:4

    Topics: Acute Disease; Aged; Brain; Brain Ischemia; Dipyridamole; Dose-Response Relationship, Drug; Female;

2000
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
    Bibliotheca haematologica, 1977, Volume: 44

    Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial

1977
Second European Stroke Prevention Study. ESPS-2 Working Group.
    Journal of neurology, 1992, Volume: 239, Issue:6

    Topics: Aspirin; Brain Ischemia; Computer Simulation; Dipyridamole; Double-Blind Method; Drug Administration

1992
European Stroke Prevention Study. ESPS Group.
    Stroke, 1990, Volume: 21, Issue:8

    Topics: Age Factors; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical T

1990
Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks.
    Acta neurologica Scandinavica, 1987, Volume: 76, Issue:6

    Topics: Adult; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; D

1987
Effect of dipyridamole plus pentoxifylline in patients with diffuse cerebrovascular insufficiency.
    Thrombosis and haemostasis, 1985, Dec-17, Volume: 54, Issue:4

    Topics: Aged; Brain Ischemia; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Female; Hum

1985

Other Studies

65 other studies available for dipyridamole and Brain Ischemia

ArticleYear
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke.
    Journal of the neurological sciences, 2022, 10-15, Volume: 441

    Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Humans; Ischemic Atta

2022
Intensive antiplatelet therapy with three agents does not reduce risk of another stroke.
    Drug and therapeutics bulletin, 2020, Volume: 58, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stroke

2020
The neuron-astrocyte-microglia triad in CA3 after chronic cerebral hypoperfusion in the rat: Protective effect of dipyridamole.
    Experimental gerontology, 2017, 10-01, Volume: 96

    Topics: Analysis of Variance; Animals; Apoptosis; Astrocytes; Brain Ischemia; CA3 Region, Hippocampal; Carot

2017
Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke.
    The American journal of cardiology, 2018, 09-15, Volume: 122, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combinati

2018
Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis.
    European journal of neurology, 2014, Volume: 21, Issue:10

    Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination;

2014
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel;

2015
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
    BMC neurology, 2015, Nov-02, Volume: 15

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies;

2015
Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment.
    Journal of the neurological sciences, 2016, Feb-15, Volume: 361

    Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Dipyr

2016
Current practice of antithrombotic treatment in ischemic stroke: a survey among Hungarian neurologists.
    Ideggyogyaszati szemle, 2008, May-30, Volume: 61, Issue:5-6

    Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Prescriptions;

2008
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Chest, 2008, Volume: 133, Issue:6 Suppl

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici

2008
Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin.
    Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:4

    Topics: Aged; Aspirin; Brain Ischemia; Cerebral Arteries; Dipyridamole; Drug Therapy, Combination; Female; H

2009
Medical treatment of patients with intracranial atherosclerotic disease.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2009, Volume: 19 Suppl 1

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb

2009
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
    Stroke, 2010, Volume: 41, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrh

2010
Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
    Current medical research and opinion, 2010, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Fema

2010
Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors.
    American journal of therapeutics, 2012, Volume: 19, Issue:6

    Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Dose-Response Relationship

2012
What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?
    JPMA. The Journal of the Pakistan Medical Association, 2010, Volume: 60, Issue:10

    Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Evidence-B

2010
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Antiplatelet therapy for transient ischemic attack.
    Journal of clinical hypertension (Greenwich, Conn.), 2012, Volume: 14, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Clopidogrel; Cognition Disorders;

2012
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Br

2013
Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.
    Stroke, 2003, Volume: 34, Issue:6

    Topics: Anticoagulants; Arterial Occlusive Diseases; Asia, Southeastern; Aspirin; Brain Ischemia; Dipyridamo

2003
Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN International Trial.
    Stroke, 2003, Volume: 34, Issue:10

    Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Brain Isc

2003
Astrocytes and neurons: different roles in regulating adenosine levels.
    Neurological research, 2005, Volume: 27, Issue:2

    Topics: Adenosine; Affinity Labels; Animals; Astrocytes; Brain Ischemia; Cells, Cultured; Deoxyglucose; Dipy

2005
Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2.
    Stroke, 2006, Volume: 37, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Male; Middle

2006
Dipyridamole plus aspirin: the best regimen for stroke prevention after noncardioembolic focal cerebral ischemia.
    Cerebrovascular diseases (Basel, Switzerland), 2006, Volume: 22, Issue:1

    Topics: Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Human

2006
ESPRIT trial.
    Lancet (London, England), 2006, Aug-05, Volume: 368, Issue:9534

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Dipyridamole; Drug Interactions; G

2006
ESPRIT trial.
    Lancet (London, England), 2006, Aug-05, Volume: 368, Issue:9534

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Dose

2006
Clinical trials and dipyridamole formulation selection.
    Cerebrovascular diseases (Basel, Switzerland), 2007, Volume: 23, Issue:1

    Topics: Aspirin; Brain Ischemia; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dipyridamole; Drug

2007
Emerging therapies: ESPRIT.
    Stroke, 2007, Volume: 38, Issue:4

    Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Dipyridamole; Drug Therapy,

2007
TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents.
    Current neurovascular research, 2007, Volume: 4, Issue:1

    Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Cells, Cultured; Clopidogrel; Dipyridamole; Fem

2007
Cerebral ischemia probably related to isotretinoin.
    The Annals of pharmacotherapy, 2007, Volume: 41, Issue:6

    Topics: Adult; Aspirin; Brain Ischemia; Dermatologic Agents; Dipyridamole; Heparin; Humans; Isotretinoin; Ma

2007
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
    Ugeskrift for laeger, 2007, Oct-01, Volume: 169, Issue:40

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents;

2007
Re: Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan.
    European journal of neurology, 2008, Volume: 15, Issue:2

    Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line, Transformed; Dipyridam

2008
The ECV-304 cell-line: should it be used?
    European journal of neurology, 2008, Volume: 15, Issue:2

    Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line; Dipyridamole; Endothel

2008
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
    Stroke, 2008, Volume: 39, Issue:5

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru

2008
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
    Ugeskrift for laeger, 2008, Mar-31, Volume: 170, Issue:14

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin;

2008
[Treatment of the syndrome of disseminated intravascular coagulation in ischemic strokes].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1984, Volume: 84, Issue:9

    Topics: Adult; Aged; alpha-Tocopherol; Blood Transfusion; Brain Ischemia; Combined Modality Therapy; Dipyrid

1984
Treatment of cerebral ischemia.
    Comprehensive therapy, 1981, Volume: 7, Issue:4

    Topics: Aspirin; Brain Ischemia; Carotid Arteries; Dicumarol; Dipyridamole; Endarterectomy; Heart Murmurs; H

1981
[Effect of ticlopidine in the prevention of recurrences of cerebral ischemic accidents: comparative study with dipyridamol].
    Medicina clinica, 1984, Jan-21, Volume: 82, Issue:2

    Topics: Brain Ischemia; Dipyridamole; Drug Evaluation; Female; Gastrointestinal Hemorrhage; Humans; Male; Re

1984
[Experimental and clinical study of the efficacy of intracarotid administration of curantil in the treatment of cerebral ischemia].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1983, Volume: 83, Issue:1

    Topics: Adult; Animals; Brain; Brain Ischemia; Carotid Artery, Internal; Catheterization; Cats; Cerebral Inf

1983
Platelet aggregation in focal cerebral ischemia -a clinical study.
    Acta neurologica Scandinavica, 1982, Volume: 65, Issue:3

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male

1982
[Platelet function inhibition and anticoagulation in coronary, cerebral and peripheral arterial occlusive disease. 2. Secondary prevention].
    Fortschritte der Medizin, 1982, May-13, Volume: 100, Issue:18

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; M

1982
[Ischemic cerebro-vascular accidents: usefulness of anticoagulant and antiaggregating agents (author's transl)].
    Revue medicale de Bruxelles, 1981, Volume: 2, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Humans; Plat

1981
[Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
    Minerva cardioangiologica, 1980, Volume: 28, Issue:10

    Topics: Aspirin; Blood Platelet Disorders; Brain Ischemia; Clofibrate; Coronary Disease; Dipyridamole; Human

1980
Effects of dipyridamole, pentoxifylline or dipyridamole plus pentoxifylline on platelet reactivity in patients with ischemic cerebrovascular insufficiency.
    Thrombosis research, 1993, Nov-01, Volume: 72, Issue:3

    Topics: Aged; Blood Platelets; Brain Ischemia; Collagen; Dipyridamole; Drug Therapy, Combination; Female; Hu

1993
Effects of dipyridamole in spontaneously hypertensive rabbits with diffuse chronic cerebral ischemia.
    European journal of pharmacology, 1993, Jun-24, Volume: 237, Issue:2-3

    Topics: Analysis of Variance; Animals; Blood Pressure; Brain Ischemia; Cerebrovascular Circulation; Dipyrida

1993
[Stroke in young people].
    Revista de neurologia, 1996, Volume: 24, Issue:126

    Topics: Adolescent; Adult; Aspirin; Brain Ischemia; Child; Dipyridamole; Female; Humans; Male; Middle Aged;

1996
Brain SPECT with dipyridamole stress to evaluate cerebral blood flow reserve in carotid artery disease.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996, Volume: 37, Issue:10

    Topics: Acetazolamide; Aged; Brain; Brain Ischemia; Carotid Artery, Internal; Carotid Stenosis; Cerebral Inf

1996
Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
    Journal of the neurological sciences, 1997, Sep-01, Volume: 150, Issue:1

    Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Humans; Platelet Aggregation Inhib

1997
[Prevention of thrombosis after ischemic cerebrovascular attack--new possibilities].
    Ugeskrift for laeger, 1998, Jul-20, Volume: 160, Issue:30

    Topics: Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Humans; Intracranial Embolism

1998
Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to a New Zealand ischaemic stroke cost analysis.
    PharmacoEconomics, 1997, Volume: 12, Issue:6

    Topics: Aspirin; Brain Ischemia; Costs and Cost Analysis; Dipyridamole; Health Care Costs; Humans

1997
Alert to physicians: possible interaction of aggrenox and adenosine.
    Journal of the American College of Cardiology, 2000, Volume: 36, Issue:4

    Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action Preparati

2000
Influence of inhibition of adenosine uptake on the gamma-aminobutyric acid level of the ischemic rat brain.
    Arzneimittel-Forschung, 2002, Volume: 52, Issue:5

    Topics: Adenosine; Animals; Biomarkers; Brain; Brain Chemistry; Brain Ischemia; Cerebral Cortex; Dipyridamol

2002
Heart-brain interactions in cerebral ischaemia: a non-invasive cardiologic study protocol.
    Neurological research, 1992, Volume: 14, Issue:2 Suppl

    Topics: Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Echocardiography; Electro

1992
[Drug treatment of ischemic disturbances of circulation in the brain].
    Duodecim; laaketieteellinen aikakauskirja, 1990, Volume: 106, Issue:20

    Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Ticlopidine

1990
Effect of dipyridamole on cerebral extracellular adenosine level in vivo.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 1990, Volume: 10, Issue:3

    Topics: Adenosine; Animals; Brain; Brain Ischemia; Cerebral Cortex; Dialysis; Dipyridamole; Extracellular Sp

1990
Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum.
    European neurology, 1985, Volume: 24, Issue:4

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Dicumarol; Dipyridamole; Drug Therapy, Combination; Female;

1985
[The effectiveness of antiplatelet therapy in ischemic cerebrovascular attacks in the chronic stage].
    Ceskoslovenska neurologie a neurochirurgie, 1989, Volume: 52, Issue:5

    Topics: Aspirin; Brain Ischemia; Dipyridamole; Female; Hemiplegia; Humans; Male; Middle Aged; Pentoxifylline

1989
Effects of two nucleoside transport inhibitors, dipyridamole and soluflazine, on purine release from the rat cerebral cortex.
    Brain research, 1989, Mar-06, Volume: 481, Issue:2

    Topics: Adenosine; Animals; Biological Transport, Active; Brain Ischemia; Cerebral Cortex; Dipyridamole; Mal

1989
[Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22-34 months)].
    Minerva medica, 1985, Oct-27, Volume: 76, Issue:41

    Topics: Adenosine Diphosphate; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Isoxsuprine; Male; Oxa

1985
Mitral valve prolapse and thromboembolic disease in pregnancy: a case report.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1988, Volume: 27, Issue:1

    Topics: Adult; Aspirin; Brain Ischemia; Contraceptives, Oral; Dipyridamole; Drug Therapy, Combination; Embol

1988
Whole blood platelet function in acute ischemic stroke. Importance of dense body secretion and effects of antithrombotic agents.
    Stroke, 1989, Volume: 20, Issue:1

    Topics: Acute Disease; Adult; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; Dipyridam

1989
Transluminal dilatation of the subclavian artery.
    Cardiovascular and interventional radiology, 1985, Volume: 8, Issue:1

    Topics: Adult; Aged; Angioplasty, Balloon; Arm; Brain Ischemia; Constriction, Pathologic; Dipyridamole; Fema

1985
Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole.
    Thrombosis research, 1987, Jan-15, Volume: 45, Issue:2

    Topics: Adenosine; Adenosine Diphosphate; Adult; Aged; Brain Ischemia; Dipyridamole; Female; Humans; In Vitr

1987
[The effect of artificial hypotension on postischemic cerebral edema in the reperfusion of middle cerebral arterial occlusion in cats--experimental study].
    No shinkei geka. Neurological surgery, 1986, Volume: 14, Issue:3 Suppl

    Topics: Adenosine Triphosphate; Animals; Body Water; Brain Chemistry; Brain Edema; Brain Ischemia; Cats; Cer

1986
[Hemodynamic disorders and various problems in treatment in strokes with reversible neurologic deficits].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1986, Volume: 86, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Bencyclane; Brain Ischemia; Dipyridamole; Diuretics;

1986